Destiny Pharma and SporeGen® announce update from research collaboration under Innovate UK grant award to develop a biotherapeutic treatment (SPOR-COV®) for COVID-19 and Influenza
Positive results from testing SPOR-COV in several COVID-19 and influenza research models support potential as prophylactic nasal spray Toxicology studies support safety profile Manufacturing process established Manufacturing and regional licensing agreement signed with HURO Biotech JSC for Vietnam Phase 1 clinical studies completed successfully in Vietnam by HURO Retail product based on SPOR COV technology […]